Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01929798 · ClinicalTrials.gov registry record · Early Phase 1
Crossover Feasibility Study of Portable AP Device With Zone-MPC and HMS and Adapted I:C and Basal Insulin
A Early Phase 1 study of Type 1 Diabetes Mellitus, sponsored by Sansum Diabetes Research Institute.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT01929798: Completed Early Phase 1 study of Type 1 Diabetes Mellitus, sponsored by Sansum Diabetes Research Institute.
NCT01929798 is a Early Phase 1 study of Type 1 Diabetes Mellitus that has completed, run by Sansum Diabetes Research Institute. The registered enrollment target is 36 participants, below the 172-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01929798, a Early Phase 1 study of Type 1 Diabetes Mellitus, has completed, sponsored by Sansum Diabetes Research Institute.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this trial is to assess the performance of an Artificial Pancreas (AP) device using the Portable Artificial Pancreas System (pAPS) platform for subjects with type 1 diabetes using an insulin pump and rapid acting insulin. This proposed study is designed to compare closed-loop control with or without optimization of initialization parameters related to basal insulin infusion rates and insulin to carbohydrate (I:C) ratios for meals and snacks.
Primary Outcome
The percentage time spent in safe blood glucose range of \[80-140\] mg/dl will be the primary endpoint. More time spent inside the desired range will be considered successful. Expected levels are \[70-180\] mg/dl the 5 hours after meals and \[70-150\] mg/dl 3 hours after exercise.
Conditions Studied
Interventions
- DEVICE portable Artificial Pancreas
Study Locations (1)
California
- Sansum Diabetes Research Institutute - Santa Barbara
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2013-11 |
| Est. Completion | 2014-11 |
| Phase | Early Phase 1 |
What the finished NCT01929798 record still lists
NCT01929798 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 172-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which portable Artificial Pancreas is the first listed.
NCT01929798 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01929798 about?
NCT01929798 is a clinical study titled "Crossover Feasibility Study of Portable AP Device With Zone-MPC and HMS and Adapted I:C and Basal Insulin". The purpose of this trial is to assess the performance of an Artificial Pancreas (AP) device using the Portable Artificial Pancreas System (pAPS) platform for subjects with type 1 diabetes using an insulin pump and rapid acting insulin. This proposed study is designed to compare closed-loop control ...
What is the current status of trial NCT01929798?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 36 participants. The study started on 2013-11. Estimated completion is 2014-11.
What conditions does trial NCT01929798 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.
What interventions are being tested in trial NCT01929798?
The interventions under investigation include: portable Artificial Pancreas (DEVICE).
Who is sponsoring clinical trial NCT01929798?
This trial is sponsored by Sansum Diabetes Research Institute, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01929798 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01929798's enrollment target sits among peer trials
36 64th of 112 higher than 47 of 112 other Type 1 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 1 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effects of Fluoxetine and/or DHEA
RECRUITING · Early Phase 1
-
Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes
RECRUITING · Early Phase 1
-
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
RECRUITING · Phase 2
-
Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes
RECRUITING · Phase 1
-
Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)
RECRUITING · Phase 1
-
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia